Skip to main content
. 2015 Feb 15;5(5):489–503. doi: 10.7150/thno.10069

Table 4.

Assesment of C6 tumor growth in mice receiving magnetoliposomes containing or not ω-3 PUFA-EE.

Type of liposomal preparation injected a) Mouse b) Initial size (mm2) c) Final size (mm2) d) % increase or decrease tumor size after treatment
None, saline Mouse 1 12.72 18.87 +48.35%
Mouse 2 38.89 131.82 +238.96%
Empty Liposomes Mouse 5 13.46 26.92 +200,00%
Mouse 6 18.37 76.23 +414,90%
Nanotex Liposomes Mouse 9 15.756 27.5 +74.54%
Mouse 10 14.473 20.212 +39.65%
Mouse 11 8.298 13.787 +66.15%
Nanotex + ω-3 PUFA-EE Liposomes Mouse 13 12.624 2.825 -77.62%
Mouse 14 6.07 0.396 -93.48%
Mouse 15 8.952 0.347 -96.12%
Mouse 16 24.377 10.179 -58.24%

a) Liposomal preparations were administered i.v. through the tail vein fifteen days after C6 cell implantation.

b) Groups containing four mice at the time of treatment initiation were used in all conditions. Only the mice surviving six days after treatment initiation are shown.

c) Tumor size before treatment initiation.

d) Tumor size after six days of treatment.

c,d) Tumor area (mm2) reflects the area including the tumor and peripheral inflammation as detected in coronal cross sections of T2w images obtained before (initial) or six days after (final) treatment.